Tareetine FGFR3 in t(4;14) mutiple myeloma: Pre-clinical studies of PRO-001, a novel anti-FGFR3 neutralizing antibody.

被引：0
|
作者：
Trudel, S
Wei, E
Li, ZH
Rom, E
Chumakov, I
Singer, Y
Chen, C
Reece, D
Mikhael, J
Stewart, AK
Yayon, A
机构：
[1] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada
[2] ProChon Biotech, Rehovot, Israel
来源：
BLOOD | 2004年 / 104卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2479
引用
收藏
页码：680A / 680A
页数：1
相关论文
共 49 条
  • [1] The inhibitory anti-FGFR3 antibody, PRO-001, is cytotoxic to t(4;14) multiple myeloma cells
    Trudel, Suzanne
    Stewart, A. Keith
    Rom, Eran
    Wei, Ellen
    Li, Zhi Hua
    Kotzer, Sarit
    Chumakov, Irina
    Singer, Yossi
    Chang, Hong
    Liang, Sheng-Ben
    Yayon, Avner
    BLOOD, 2006, 107 (10) : 4039 - 4046
  • [2] FGFR3 amplification in the absence of IGH@-FGFR3 fusion t(4;14) in myeloma
    Quintero-Rivera, Fabiola
    Badr, Riem El-Sabbagh
    Rao, P. Nagesh
    CANCER GENETICS AND CYTOGENETICS, 2009, 195 (01) : 92 - 93
  • [3] Analysis of FGFR3 gene mutations in multiple myeloma patients with t(4;14)
    Intini, D
    Baldini, L
    Fabris, S
    Lombardi, L
    Ciceri, G
    Maiolo, AT
    Neri, A
    BRITISH JOURNAL OF HAEMATOLOGY, 2001, 114 (02) : 362 - 364
  • [4] The t(4;14) translocation and FGFR3 overexpression in multiple myeloma: prognostic implications and current clinical strategies
    Kalff, A.
    Spencer, A.
    BLOOD CANCER JOURNAL, 2012, 2 : e89 - e89
  • [5] The t(4;14) translocation and FGFR3 overexpression in multiple myeloma: prognostic implications and current clinical strategies
    A Kalff
    A Spencer
    Blood Cancer Journal, 2012, 2 : e89 - e89
  • [6] Immunohistochemistry accurately predicts FGFR3 aberrant expression and t(4;14) in multiple myeloma
    Chang, H
    Stewart, AK
    Qi, XY
    Li, ZH
    Yi, QL
    Trudel, S
    BLOOD, 2005, 106 (01) : 353 - 355
  • [7] Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice
    Qing, Jing
    Du, Xiangnan
    Chen, Yongmei
    Chan, Pamela
    Li, Hao
    Wu, Ping
    Marsters, Scot
    Stawicki, Scott
    Tien, Janet
    Totpal, Klara
    Ross, Sarajane
    Stinson, Susanna
    Dornan, David
    French, Dorothy
    Wang, Qian-Rena
    Stephan, Jean-Philippe
    Wu, Yan
    Wiesmann, Christian
    Ashkenazi, Avi
    JOURNAL OF CLINICAL INVESTIGATION, 2009, 119 (05): : 1216 - 1229
  • [8] Inhibition of FGFR3 in t(4;14) multiple myeloma: Validation of a therapeutic target.
    Trudel, SM
    Ely, S
    Farooqi, Y
    Affer, M
    Robbiani, DF
    Chesi, M
    Bergsagel, PL
    CLINICAL CANCER RESEARCH, 2003, 9 (16) : 6129S - 6129S
  • [9] LY3076226, a novel anti-FGFR3 antibody drug conjugate exhibits potent and durable anti-tumor activity in tumor models harboring FGFR3 mutations or fusions
    Surguladze, David
    Pennello, Anthony
    Ren, Xiaodi
    Mack, Tim
    Rigby, Alan
    Balderes, Paul
    Navarro, Elizabeth
    Amaladas, Nelusha
    Eastman, Scott
    Topper, Michael
    Yao, Yung-Mae
    Moxham, Chris
    Plowman, Gregory
    Ludwig, Dale
    CANCER RESEARCH, 2019, 79 (13)
  • [10] A novel mutation involving the carboxy terminal region of the FGFR3 gene in a multiple myeloma patient with t(4;14)
    D Intini
    L Baldini
    L Lombardi
    A Neri
    Leukemia, 2002, 16 : 1201 - 1202
12345